BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Aug 25, 2003
 |  BioCentury  |  Emerging Company Profile

direvo: Applied Darwinism

Recombinant proteins are used in many industrial and medical applications, but often they bear only a passing resemblance to naturally occurring molecules and are not optimized for their purpose. direvo AG's goal is to optimize recombinant proteins using directed evolution. Instead of using naturally occurring diversity or modifying the protein itself, direvo modifies the genes, an approach the company believes is faster and more versatile because genes can be modified faster and more easily than proteins.
"One can improve product features a lot this way," President and CEO Andre Koltermann told BioCentury. "One can think of improvements in stability, catalytic activity, potency, efficacy, selectivity, binding constant and side effects of recombinant proteins, enzymes, cytokines, antibodies, industrial enzymes, biocatalysts and the like. Even marketed products can be improved. As an example, we have enhanced the specific activity of marketed proteins by a factor of up to...

Read the full 694 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >